Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Abbott Laboratories

ABT
$88.82 (+ $0.46 + 0.52%)
Last updated: Previous Close (2026-05-19)
ABT Metrics
Exchange
🇺🇸 NYSE XNYS
New York Stock Exchange, Inc.United StatesAmerica/New_York
SectorHealthcare
IndustryMedical Devices
ISINUS0028241000
Market Price88.82
Dividend Yield 2.87%
Dividend Growth
1Y +7.14%
3Y +11.03%
5Y +12.25%
10Y +7.50%
Annual Dividend 2.40
Latest Payout ($)0.63
Latest Payout Date2026-05-16
Dividend FrequencyQuarterly
P/E Ratio23.78
EPS3.72
Market Cap$186.8B
Book Value29.3
Price to Book4.25
Beta0.17
52w High139.06
52w Low81.97
Next Earnings DateN/A
About the Company
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of health care products worldwide. It operates across four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, addressing needs from chronic disease management to acute diagnostics. The company offers generic pharmaceuticals treating conditions such as pancreatic exocrine insufficiency, irritable bowel syndrome, dyslipidemia, hypertension, hypothyroidism, pain, fever, inflammation, and migraine, alongside anti-infectives, influenza vaccines, and gastrointestinal regulators. Notable products include cardiovascular devices like pacemakers and stents, diabetes management tools such as continuous glucose monitors, pediatric and adult nutritional formulas, and advanced diagnostic equipment like immunoassays and point-of-care testing kits. With approximately 114,000 employees and a history dating back to 1888, Abbott Laboratories generates the majority of its sales outside the United States, playing a pivotal role in advancing medical innovation, improving patient outcomes, and supporting global health initiatives through its extensive reach in consumer, institutional, and professional markets.
Price History
Latest News for ABT
10 Quality Stocks That Hit New Lows This Week—and Look Like Bargains
Even as tech surges, many other sectors in the market are trading at surprisingly attractive prices.
Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks.
Even as tech surges, many other sectors in the market are trading at surprisingly attractive prices.
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
Abbott Laboratories (NYSE:ABT) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer highlighted it as one of the “greatest American companies,” as he said: …Let’s talk about some similarities that have now been popping up, okay? In 1999, we saw […]
How The Investment Narrative For Abbott Laboratories (ABT) Is Shifting With Recent Analyst Resets
Abbott Laboratories is under fresh scrutiny as price targets are reset, with some analysts trimming their expectations and others keeping fair value estimates such as US$118.64 broadly intact. The more cautious tone in recent research, including cuts to targets and removal from a key US conviction list, sits alongside ongoing supportive views that still see room for upside versus analysts’ own fair value work. As you read on, you will see how to track these shifting targets and use the...
Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.
Australia Regenerative Medicine Market Research Trends and Forecasts Report 2026-2035 Featuring Prominent Players Such as Abbott Laboratories, Astellas Pharma, and Roche
The Australia regenerative medicine market offers significant opportunities in cellular therapies, tissue engineering, and aesthetic applications, driven by aging populations and chronic disease prevalence. Key growth is seen in oncological applications and hospital adoption, with strong government backing and technological advancements enhancing potential.Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Australia Regenerative Medicine Market - Distribution by Type of Products, Type of Therapeutic